Seaport Therapeutics priced its upsized IPO at $18 per share, issuing 14.16 million shares.
The company expects gross proceeds of $254.9 million before underwriting discounts, commissions and offering expenses.
Underwriters have a 30‑day option to buy an additional 2.124 million shares at the IPO price.
Shares will start trading on Nasdaq Global Select Market on May 1, 2026 under ticker “SPTX”, with the offering closing May 4, 2026.